Belgium · Delayed Price · Currency is EUR argenx SE Earnings Call Transcripts
Fiscal Year 2026
-
The discussion outlined a robust growth and innovation strategy, with near-term clinical readouts in myositis, MMN, and Sjögren's, and a strong FcRn franchise expansion. VYVGART maintains leadership in MG, while new programs and flexible dosing aim to address unmet needs and broaden market reach.
-
VYVGART continues to drive strong patient outcomes and commercial growth, with 19,000 patients treated and significant expansion into new indications like seronegative and ocular MG. The pipeline is robust, with multiple late-stage assets and innovative therapies advancing, supporting ambitious 2030 impact goals.
Fiscal Year 2025
-
Achieved 90% year-over-year net sales growth to $4.2B in 2025, driven by strong VYVGART adoption and label expansion opportunities in MG and CIDP. Positive phase III ocular MG results and robust pipeline support long-term growth and profitability.
-
Record quarterly net sales of $1.13B driven by VYVGART growth in gMG and CIDP, with strong PFS adoption and expanding global reach. Pipeline advances include three phase III assets and five registration readouts expected next year, supporting long-term growth.
-
argenx 119, a MuSK agonist antibody, is advancing rapidly in CMS, ALS, and SMA, with phase 1B data in DOK7 CMS showing strong proof of biology, safety, and meaningful functional improvements. The program leverages digital endpoints, innovative trial designs, and deep academic partnerships to accelerate development and expand to additional neuromuscular indications.
-
Strong commercial execution and profitability are driving growth, with Vyvgart expanding in MG and CIDP and a robust late-stage pipeline targeting multiple new indications. Innovation in delivery, AI, and academic partnerships support long-term goals, while market expansion and new assets underpin Vision 2030.
-
The company is rapidly expanding its FcRn franchise, with VYVGART adoption moving earlier in treatment and new product presentations driving growth. Multiple phase III readouts and pipeline innovations are expected to significantly expand market potential and sustain long-term growth.
-
VYVGART delivered 97% year-over-year sales growth, driven by strong uptake in MG and CIDP, with the prefilled syringe launch expanding patient and prescriber reach. Operating income rose to $967 million, and the company maintains a robust pipeline and strong cash position, supporting continued growth and innovation.
-
Long-term strategies in manufacturing and pricing are mitigating policy risks, while product innovation and strong financials support continued growth. PFS launch is expanding the patient base, and new pipeline programs are on track for Vision 2030.
-
Disciplined global pricing and localized supply chain mitigate macro and regulatory risks. Q1 saw 7% revenue growth, with strong new patient and prescriber trends, especially for Hytrulo and PFS. Multiple phase 3 and 2 readouts are expected through 2025–2026, supporting continued innovation and market expansion.
-
Q1 2025 saw 99% year-over-year revenue growth, driven by strong VYVGART demand in gMG and CIDP, and the launch of a pre-filled syringe for self-injection. Robust pipeline progress and international expansion support sustained growth, with a strong financial position and continued investment in innovation.
-
Rapid patient uptake in CIDP was achieved through strong market access and educational efforts, with most new patients switching from IVIG. The pipeline is advancing across multiple indications, including myositis and MG, with innovative trial designs and a focus on early intervention. Strategic flexibility is maintained for next-gen assets and pricing.
-
Transformative innovation in rare autoimmune diseases is driving strong clinical and commercial momentum, with VYVGART and pipeline assets expanding into new indications. Strategic priorities for 2025 include broadening patient access, advancing a robust pipeline, and scaling manufacturing to support ambitious growth targets.
Fiscal Year 2024
-
Q4 and full-year 2024 saw robust revenue growth, strong gross margins, and a transition to profitability, driven by expanding adoption in MG and CIDP and pipeline progress. 2025 guidance reflects increased R&D investment and anticipated regulatory milestones, including U.S. approval for self-injection.
-
Strong commercial execution in 2024 drove growth in MG and CIDP, with linear momentum expected to continue. Pipeline advances include phase III programs in myositis, Sjögren's, and MMN, while financial strength supports scaling and innovation. Vision 2030 targets five late-stage molecules and 10 indications.
-
Early achievement of strategic milestones and robust launches in MG and CIDP are driving growth, with strong payer access and international expansion. Pipeline progress includes imminent myositis and bullous pemphigoid data, next-gen therapies, and a solid financial position supporting innovation.
-
Q3 2024 saw 20% sequential and 74% year-over-year product sales growth, driven by strong MG and CIDP launches, with Vyvgart Hytrulo reaching over 300 CIDP patients and robust global expansion. Operating profit was $14M, net profit $91M, and cash rose to $3.4B. Discontinuation of MN program reflects focus on high-impact indications.
-
Innovation and pipeline expansion remain central, with strong execution in CIDP and MG, and new products like subQ Vyvgart and EMPA advancing. Next-gen FcRn and myositis trials are key near-term milestones, while robust financials support ongoing R&D.
-
Q2 2024 saw $489M in operating income and 20% sequential sales growth, with MG driving results and CIDP launch underway. Strong cash reserves and pipeline progress support Vision 2030, while payer policy adoption and competition remain key risks.
-
Vision 2030 aims for 50,000 patients, 10 indications, and 5 new phase 3 molecules, driven by a robust innovation engine and commercial playbook. Pipeline advances include ARGX-213, ARGX-121, and empasiprubart, with strong clinical data in MMN and ongoing expansion in MG, CIDP, and Sjögren's.
-
FDA approved VYVGART Hytrulo for CIDP, introducing the first new mechanism in over 30 years. Approval was based on robust ADHERE trial data showing rapid, durable efficacy and a favorable safety profile. Launch targets 12,000 U.S. patients not well managed on current therapies, with global expansion and payer negotiations underway.
-
Major catalysts include the imminent CIDP approval, multiple phase II data readouts, and the PFS filing for MG and CIDP. Launch strategies leverage existing infrastructure, with pricing and access aligned to MG. Pipeline adjustments and strong European growth support long-term expansion.